SRX Global (SRXH) Q3 2026 earnings summary

Executive summary

• Completed the acquisition of EMJX/EMJC, transitioning to focus on premium pet health products and AI-driven digital asset treasury management, and discontinued Canadian healthcare operations.

• Ended the quarter with $62.9 million in net asset value ($3.22 per share), $36.7 million in cash, and a highly liquid, debt-free balance sheet.

• Achieved record Halo operational metrics, including a 98% supply chain fill rate and strong Prime Day performance.

• Completed a one-for-60 reverse stock split to regain NYSE American compliance.

• Announced a one-time $0.05/share cash dividend and authorized a $20 million share repurchase program, with no repurchases made yet due to blackout period.

Financial highlights

• Net sales for Q3 totaled $3.4 million, up 27% year-over-year, with a gross margin of 27%.

• Operating loss improved 63% year-over-year to $3.2 million; net loss from continuing operations was $4.1 million, improving 40% year-over-year.

• Adjusted EBITDA loss improved 35% year-over-year to $1.6 million.

• Exchange-traded option activity generated $600,000 in net gains for the quarter and $1.2 million year-to-date.

• Cash and equivalents totaled $36.7 million as of quarter end, with $7.5 million in short-term investments.

Outlook and guidance

• Management is focused on stabilizing operations, optimizing cost structure, and pursuing growth aligned with the new business model, including supporting Halo growth and phased EMJX deployment.

• Expect continued gross margin expansion over the next 12 months due to ongoing strategic initiatives.

• No current plans for capital raises; sufficient liquidity to execute the existing strategy.